JAAD Game Changers: Dupilumab shows long-term safety and efficacy in patients with moderate-to-severe atopic dermatitis enrolled in a phase 3 open-label extension study

被引：0
|
作者：
Wohltmann, Wendi E. [1 ]
机构：
[1] San Antonio Mil Med Ctr, Dermatol & Pathol, 1100 Wilford Hall Loop, Jbsa Lackland, TX 78236 USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2024年 / 91卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：613 / 613
页数：1
相关论文
共 50 条
  • [21] Long-term efficacy of dupilumab in adults with moderate-to-severe atopic dermatitis: Results from an open-label extension trial up to 172 weeks
    Beck, L.
    Deleuran, M.
    Blauvelt, A.
    Thyssen, J.
    Bissonnette, R.
    de Bruin-Weller, M.
    Chen, Z.
    Levit, N.
    Rodriguez Marco, A.
    EXPERIMENTAL DERMATOLOGY, 2021, 30 : 11 - 12
  • [22] Safety and efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: an open-label study
    Paller, Amy
    Flohr, Carsten
    Eichenfield, Lawrence F.
    Irvine, Alan D.
    Pinto-Correia, Ana
    Natalie, Chitra R.
    Pierce, Evangeline
    Reifeis, Sarah
    Lima, Renata Gontijo
    Laquer, Vivian
    Weidinger, Stephan
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 60 - 61
  • [23] Safety and efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: an open-label study
    Paller, Amy
    Flohr, Carsten
    Eichenfield, Lawrence F.
    Irvine, Alan
    Pinto-Correia, Ana
    Natalie, Chitra R.
    Pierce, Evangeline
    Reifeis, Sarah
    Lima, Renata Gontijo
    Laquer, Vivian
    Weidinger, Stephan
    Isho, Nadine
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
  • [24] Safety and efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: an open-label study
    Paller, Amy
    Flohr, Carsten
    Eichenfield, Lawrence F.
    Irvine, Alan
    Correia, Ana Pinto
    Natalie, Chitra R.
    Pierce, Evangeline
    Lima, Renata Gontijo
    Laquer, Vivian
    Weidinger, Stephan
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB84 - AB84
  • [25] LONG-TERM SAFETY DATA FOR DUPILUMAB IN A 5-YEAR OPEN- LABEL EXTENSION STUDY OF ADULTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
    Beck, Lisa A.
    Bissonnette, Robert
    Deleuran, Mette
    Nakahara, Takeshi
    Galus, Ryszard
    Khokhar, Faisal A.
    Coleman, Anna
    Gherardi, Guy
    Xiao, Jing
    Dingman, Robert
    Xu, Christine
    Avetisova, Elena
    Dubost-Brama, Ariane
    Shabbir, Arsalan
    ACTA DERMATO-VENEREOLOGICA, 2023, 103 : 52 - 52
  • [26] Efficacy and safety of switching from dupilumab to upadacitinib in moderate-to-severe atopic dermatitis: results from an open-label extension trial
    Blauvelt, A.
    Ladizinski, B.
    Prajapati, V. H.
    Laquer, V.
    Fischer, A.
    Eisman, S.
    Wu, T.
    Vigna, N.
    Teixeira, H. D.
    Liu, J.
    Eyerich, K.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (04) : E142 - E142
  • [27] Safety of long-term dupilumab treatment in adults with moderate-to-severe atopic dermatitis: results from an open-label extension trial up to 5 years
    Beck, Lisa A.
    Bissonnette, Robert
    Deleuran, Mette
    Nakahara, Takeshi
    Galus, Ryszard
    Khokhar, Faisal A.
    Coleman, Anna
    Gherardi, Guy
    Xiao, Jing
    Dingman, Robert
    Xu, Christine
    Avetisova, Elena
    Dubost-Brama, Ariane
    Shabbir, Arsalan
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
  • [28] 416 Long-term efficacy of dupilumab in adults with moderate-to-severe atopic dermatitis: results from an open-label extension trial up to 5 years
    Beck, Lisa A.
    Bissonnette, Robert
    Deleuran, Mette
    Nakahara, Takeshi
    Galus, Ryszard
    Khokhar, Faisal A.
    Coleman, Anna
    Gherardi, Guy
    Xiao, Jing
    Dingman, Robert
    Xu, Christine
    Avetisova, Elena
    Dubost-Brama, Ariane
    Shabbir, Arsalan
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
  • [29] Laboratory safety of dupilumab for up to 3 years in adults with moderate-to-severe atopic dermatitis: results from an open-label extension study
    Beck, Lisa A.
    Thaci, Diamant
    Deleuran, Mette
    de Bruin-Weller, Marjolein
    Chen, Zhen
    Khokhar, Faisal A.
    Zhang, Meng
    Ozturk, Zafer E.
    Shumel, Brad
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (03) : 1608 - 1616
  • [30] An open-label phase IIa trial assessing the pharmacokinetics, safety and efficacy of dupilumab in a paediatric population with moderate-to-severe atopic dermatitis
    Cork, M. J.
    Thaci, D.
    Davis, J. D.
    Zhang, Q.
    Akinlade, B.
    Graham, N. M. H.
    Pirozzi, G.
    Bansal, A.
    BRITISH JOURNAL OF DERMATOLOGY, 2017, 177 : 67 - 68
12345